Related Experiment Video
Updated: Aug 23, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
Oligometastatic Prostate Cancer: Current Status and Future Challenges
Hossein Jadvar1, Andre Luis Abreu2, Leslie K Ballas3
1Department of Radiology, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California; jadvar@med.usc.edu.
Summary
Oligometastatic prostate cancer, characterized by few metastases, may be treated with metastasis-directed therapy. This approach shows promise in delaying disease progression and improving patient outcomes, though further research is needed.
Area of Science:
- Oncology
- Translational Medicine
Background:
- Oligometastatic disease represents an intermediate stage in cancer progression, featuring a limited number of metastatic lesions.
- This state is increasingly recognized in prostate cancer, particularly with advancements in imaging like prostate-specific membrane antigen (PSMA)-targeted PET tracers.
Approach:
- This review examines the current understanding and challenges in managing oligometastatic prostate cancer.
- It synthesizes findings from early clinical trials investigating metastasis-directed therapy for oligometastases.
Key Points:
- Metastasis-directed therapy for oligometastatic prostate cancer may delay systemic treatment and improve outcomes in select patients.
- New-generation imaging agents, such as PSMA-targeted PET tracers, have enhanced the identification of oligometastatic disease.
- Further investigation is required into the biology of oligometastatic prostate cancer and the development of predictive biomarkers.
Conclusions:
- Oligometastatic prostate cancer is a rapidly evolving clinical area with therapeutic potential.
- Optimizing treatment strategies and identifying predictive biomarkers are crucial for improving patient outcomes.
